
Overview
Device and therapy firm's preliminary Q4 revenue rose 20% yr/yr to $10.4 mln
Company expects 2026 revenue between $54 mln and $60 mln
Preliminary results show growth in neurosurgery disposables and biologics delivery
Outlook
ClearPoint Neuro expects 2026 revenue between $54 mln and $60 mln
Company anticipates double-digit growth in all four existing markets in 2026
ClearPoint Neuro plans commercial launch of neuro cell and gene therapies in future
Result Drivers
NEUROSURGERY AND BIOLOGICS GROWTH - Functional neurosurgery disposables and biologics and drug delivery saw growth rates of 23% and 26% respectively, according to CEO Joe Burnett
IRRAFLOW CONTRIBUTION - Revenue growth partially included sales from the newly acquired IRRAflow product line
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Slight Beat* | $10.40 mln | $10.30 mln (2 Analysts) |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Clearpoint Neuro Inc is $29.00, about 94.4% above its January 9 closing price of $14.92
Press Release: ID:nACSSSgFDa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.